מוקדם מדי לבטל נעילה רץ overall respons rate רזה רטט מראש
Durable Response Rate
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Journal of Clinical Oncology
Best Overall Response Rate (full analysis population) | Download Table
Overall Response Rate of 76% in Advanced Melanoma Patients